Self-Injected Antiplatelet for Acute MI Enters Phase 3 Testing
Medscape,
A phase 3 study testing the safety and efficacy of the fast-acting, self-administered P2Y12 receptor antagonist selatogrel (Idors…
A phase 3 study testing the safety and efficacy of the fast-acting, self-administered P2Y12 receptor antagonist selatogrel (Idors…
Ad hoc announcement pursuant to Art. 53 LR Idorsia to host an investor webcast to discuss the Phase 3 study today at 14:30hrs…
Idorsia to host an investor webcast to discuss the Phase 3 study today at 14:30hrs CEST Idorsia Ltd (SIX: IDIA) today announced…
June 28, 2021 Ad hoc announcement pursuant to Art. 53 LR Idorsia to host an investor webcast to discuss the Phase 3 study today…
53 LR hoc announcement pursuant to Art. 53 LR Switzerland – June 28, 2021 Idorsia Ltd (SIX: IDIA) today announced the…
By: GlobenewsWire - 28 Jun 2021 Ad hoc announcement pursuant to Art. 53 LR Idorsia to host an investor webcast to discuss the…
Ad hoc announcement pursuant to Art. 53 LR Idorsia to host an investor webcast to discuss the Phase 3 study today at 14:30hrs…
Ad hoc announcement pursuant to Art. 53 LR Idorsia to host an investor webcast to discuss the Phase 3 study today at 14:30hrs…
Ad hoc announcement pursuant to Art. 53 LR Idorsia to host an investor webcast to discuss the Phase 3 study today at 14:30hrs…
An AMI, or heart attack, is a life-threatening condition that occurs when blood flow to the heart muscle (myocardium) is…
Idorsia to host an investor webcast to discuss the Phase 3 study today at 14:30hrs CEST Idorsia Ltd (SIX: IDIA) today announced…
Ad hoc announcement pursuant to Art. 53 LR Idorsia to host an investor webcast to discuss the Phase 3 study today at 14:30hrs…
Ad hoc announcement pursuant to Art. 53 LR Idorsia to host an investor webcast to discuss the Phase 3 study today at 14:30hrs…
Ad hoc announcement pursuant to Art. 53 LR Idorsia to host an investor webcast to discuss the Phase 3 study today at 14:30hrs…
Ad hoc announcement pursuant to Art. 53 LR Idorsia to host an investor webcast to discuss the Phase 3 study today at 14:30hrs…
Ad hoc announcement pursuant to Art. 53 LR Idorsia to host an investor webcast to discuss the Phase 3 study today at 14:30hrs…
Ad hoc announcement pursuant to Art. 53 LR Idorsia to host an investor webcast to discuss the Phase 3 study today at 14:30hrs…
Ad hoc announcement pursuant to Art. 53 LR Idorsia to host an investor webcast to discuss the Phase 3 study today at 14:30hrs…
Il nuovo inibitore P2Y12 reversibile selatogrel, somministrato per iniezione sottocutanea, sicuro e provoca una rapida risposta…
Cardiology > Prevention Recent developments of interest in cardiovascular medicine The Kawasaki disease-like multisystem…
A single dose of selatogrel can safely provide heart attack patients with a “profound, rapid” antiplatelet response, according…